Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
Anna CzarnaJinhua WangDiana ZelencovaYao LiuXianming DengHwan Geun ChoiTinghu ZhangWenjun ZhouJae Won ChangHanne KildalsenOle Morten SeternesNathanael S GrayRichard Alan EnghUlli RothweilerPublished in: Journal of medicinal chemistry (2018)
DYRK1A is one of five members of the dual-specificity tyrosine (Y) phosphorylation-regulated kinase (DYRK) family. The DYRK1A gene is located in the Down syndrome critical region and regulates cellular processes related to proliferation and differentiation of neuronal progenitor cells during early development. This has focused research on its role in neuronal degenerative diseases, including Alzheimer's and Down syndrome. Recent studies have also shown a possible role of DYRK1A in diabetes. Here we report a variety of scaffolds not generally known for DYRK1A inhibition, demonstrating their effects in in vitro assays and also in cell cultures. These inhibitors effectively block the tau phosphorylation that is a hallmark of Alzheimer's disease. The crystal structures of these inhibitors support the design of optimized and novel therapeutics.
Keyphrases
- protein kinase
- type diabetes
- transcription factor
- cognitive decline
- single cell
- signaling pathway
- small molecule
- tyrosine kinase
- genome wide
- stem cells
- tissue engineering
- high throughput
- dna methylation
- structural basis
- cerebral ischemia
- mild cognitive impairment
- subarachnoid hemorrhage
- insulin resistance
- case control